NCT01395602View on ClinicalTrials.gov

Effect of Cabergoline on Weight and Glucose Tolerance

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

September 30, 2003

Study Completion Date

July 31, 2011

Conditions
Body WeightImpaired Glucose Tolerance in Obese
Interventions
DRUG

Cabergoline

cabergoline 0.5 mg twice weekly

OTHER

placebo

1 pill twice weekly

Trial Locations (1)

10032

Columbia University, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT01395602 - Effect of Cabergoline on Weight and Glucose Tolerance | Biotech Hunter | Biotech Hunter